Form 4: Haemonetics Director Abernathy Acquires 2,207 Shares of Common Stock

Director Robert E. Abernathy acquired 2,207 shares of Haemonetics Corp common stock in the form of restricted stock units, vesting on the first anniversary of the grant date.

Summary

• On July 25, 2024, Robert E. Abernathy, a director of Haemonetics Corp, acquired 2,207 shares of common stock.
• The acquisition was in the form of restricted stock units (RSUs) granted under the company's Amended and Restated 2019 Long-Term Incentive Compensation Plan.
• These RSUs vest 100% on the first anniversary of the grant date.
• Each RSU represents a contingent right to receive one share of Haemonetics Corp common stock when vested.
• Following the transaction, Abernathy beneficially owns 22,288 shares of Haemonetics Corp common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard transaction of stock acquisition by a company director. It suggests confidence but doesn't provide strong positive or negative signals.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions and doesn't provide specific insights into broader industry trends.

Stakeholder Impact

• The acquisition of shares by a director could have a slightly positive impact on shareholder sentiment.

Key Dates